文献速递慢阻肺

他汀类药物对慢阻肺影响的随机对照试验荟萃分析

Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Chest · 2017-08-25

他汀治疗与运动能力、肺功能和圣乔治呼吸问卷评分改善相关,但炎症标志物、全因死亡率和安全性结局无统计学显著差异;亚组分析提示在合并心血管疾病、基线C反应蛋白升高或高胆固醇的患者中临床结局改善。

要点

  • 他汀治疗与慢阻肺患者运动能力、肺功能及生活质量评分改善相关。
  • 总体炎症标志物、全因死亡率和安全性结局无统计学显著差异。
  • 合并心血管疾病、基线CRP升高或高胆固醇者可能获益更明显。

核心结论

  • 他汀类药物可能对合并心血管疾病、存在全身炎症证据或高脂血症的慢阻肺患者改善运动耐量和肺功能有益。
  • 上述发现需专门设计的随机对照试验验证并确定适合他汀治疗的患者。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE、Cochrane数据库和PubMed。
  • 采用随机效应模型计算合并估计值,使用I2统计量评估异质性。

主要发现

  • 与安慰剂相比,他汀治疗与运动能力、肺功能和圣乔治呼吸问卷评分更大改善相关。
  • 炎症标志物、全因死亡率和安全性结局无统计学显著差异。
  • 亚组分析提示在合并明确心血管疾病、基线C反应蛋白升高或高胆固醇水平的试验受试者中他汀改善临床结局。

临床怎么用

  • 对合并心血管疾病、全身炎症证据或高脂血症的慢阻肺患者,可考虑他汀治疗以改善运动耐量和肺功能。
  • 不宜仅基于慢阻肺诊断普遍处方他汀,应结合合并症和炎症/血脂状态个体化评估。

局限性

  • 亚组分析结果需谨慎解读,尚不能确定最适合他汀治疗的患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Much controversy persists regarding the place of statin drugs in the treatment of patients with COPD. This systematic review and meta-analysis sought to determine the clinical efficacy of statin therapy in COPD. METHODS: We searched MEDLINE, EMBASE, the Cochrane Database, and PubMed for relevant clinical studies. Randomized controlled trials (RCTs) comparing the effects of statin drugs with placebo in COPD populations were included. Pooled estimates were calculated using a random-effects model. Heterogeneity was determined using the I2 statistic. RESULTS: Ten trials with a total of 1,471 patients were included. Statin treatment was associated with a larger improvement in exercise capacity, lung function, and St. George's Respiratory Questionnaire score compared with placebo, but there were no statistically significant differences in inflammatory markers, all-cause mortality, and safety outcomes; however, subgroup analysis indicated that statin drugs improved clinical outcomes in the subjects from trials enrolling patients with overt cardiovascular disease (CVD), elevated baseline C-reactive protein levels, or a high cholesterol level. CONCLUSIONS: The findings from this systematic review suggest a role for statin drugs in patients with COPD and coexisting CVD, evidence of increased systemic inflammation, or hyperlipidemia with respect to improving exercise tolerance and pulmonary function. These findings need to be confirmed by RCTs specifically designed to test this hypothesis and identify appropriate patients for statin use. TRIAL REGISTRY: PROSPERO: CRD42017060594; https://www.crd.york.ac.uk/PROSPERO/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhang W, Zhang Y, Li CW, et al. Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials. Chest. 2017. PMID: 28847550. doi:10.1016/j.chest.2017.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。